Market Overview

Compugen Achieves Milestone Event With Bayer


Compugen Ltd. (NASDAQ: CGEN) announced on Monday it has achieved a first preclinical milestone for CGEN-15022 as part of a cancer immunotherapy agreement with Bayer.

The companies entered into a collaboration and license agreement in 2013 for the development of anitbody-based cancer immune therapeutics. As part of the agreement, Compugen received an upfront payment of $10 million and could receive over $500 million in milestone payments for both checkpoint programs.

The collaboration provides for the research, development and commercialization of antibody-based cancer therapeutics against 2 novel Compugen-discovered immune checkpoint regulators, CGEN-15001T and CGEN-15022.

Compugen further stated in a regulatory filing that it stands to receive a $400,000 payment from Bayer.

Shares of Compugen were trading higher by 1.60 percent at $6.97 early Monday afternoon.


Related Articles (CGEN)

View Comments and Join the Discussion!

Posted-In: Bayer Cancer Therapies CGEN-15001T CGEN-15022 CompugenNews

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at